SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    K. Migita, Y. Izumi, Y. Jiuchi, H. Kozuru, C. Kawahara, M. Izumi, T. Sakai, M. Nakamura, S. Motokawa, T. Nakamura, A. Kawakami, Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis, Clinical & Experimental Immunology, 2014, 175, 2
  2. 2
    Kunihiro Yamaoka, Yoshiya Tanaka, Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 103

    CrossRef

  3. 3
    Abdullah Alghasham, Zafar Rasheed, Therapeutic targets for rheumatoid arthritis: Progress and promises, Autoimmunity, 2014, 47, 2, 77

    CrossRef

  4. 4
    Meredith A Wylie, Charles J Malemud, Deregulation of apoptosis in arthritis by altered signal transduction, International Journal of Clinical Rheumatology, 2013, 8, 4, 483

    CrossRef

  5. 5
    Ying He, Angel YS Wong, Esther W Chan, Wallis CY Lau, Kenneth KC Man, Celine SL Chui, Alan J Worsley, Ian CK Wong, Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, BMC Musculoskeletal Disorders, 2013, 14, 1, 298

    CrossRef

  6. 6
    Akiko Okamoto, Keishi Fujio, Tomohisa Okamura, Yukiko Iwasaki, Kazuhiko Yamamoto, JAK inhibition and modulation of T cell function, Inflammation and Regeneration, 2013, 33, 3, 143

    CrossRef

  7. 7
    Soumya D. Chakravarty, Poulikos I. Poulikakos, Lionel B. Ivashkiv, Jane E. Salmon, George D. Kalliolias, Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis, Clinical Immunology, 2013, 148, 1, 66

    CrossRef

  8. 8
    Guiyun Cui, Tao Zuo, Qiuchen Zhao, Jinxia Hu, Peisheng Jin, Hui Zhao, Jia Jing, Jienan Zhu, Hao Chen, Bin Liu, Fang Hua, Xinchun Ye, ROCK mediates the inflammatory response in thrombin induced microglia, Neuroscience Letters, 2013, 554, 82

    CrossRef

  9. 9
    Satoshi Kubo, Kunihiro Yamaoka, Yoshiya Tanaka, Role of JAKs in myeloid cells and autoimmune diseases, Inflammation and Regeneration, 2013, 33, 3, 131

    CrossRef

  10. 10
    A. Heine, P. Brossart, D. Wolf, Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?, Blood, 2013, 122, 23, 3843

    CrossRef

  11. 11
    Ronald F. van Vollenhoven, Small molecular compounds in development for rheumatoid arthritis, Current Opinion in Rheumatology, 2013, 25, 3, 391

    CrossRef

  12. 12
    David L Simmons, Targeting kinases: a new approach to treating inflammatory rheumatic diseases, Current Opinion in Pharmacology, 2013, 13, 3, 426

    CrossRef

  13. 13
    A. Heine, S. A. E. Held, S. N. Daecke, S. Wallner, S. P. Yajnanarayana, C. Kurts, D. Wolf, P. Brossart, The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, 2013, 122, 7, 1192

    CrossRef